Exponential Progression in Targeted Protein Degradation (TPD) Drug Discovery: New Modality Accelerates Drug Development

July 19, 2026

MarinBio USA

Overview

MarinBio published an article highlighting the exponential progression in Targeted Protein Degradation (TPD) drug discovery, establishing it as a primary, accelerating modality in novel drug development. TPD technology offers previously impossible therapeutic approaches by degrading ‘undruggable’ target proteins that conventional small molecule inhibitors could not address. Specifically, optimized design of PROTACs and utilization of diverse E3 ubiquitin ligases are significantly expanding pipeline opportunities and clinical application potential. This advancement will bring innovative treatment options across a wide range of diseases, including cancer, neurodegenerative, and inflammatory conditions.

In Depth

Key Findings

MarinBio published an article reporting that the field of Targeted Protein Degradation (TPD) drug discovery is undergoing exponential progression, establishing itself as one of the most promising and innovative modalities in next-generation pharmaceutical development. TPD technology holds groundbreaking potential to provide therapeutic solutions for ‘undruggable’ targets that conventional small molecule inhibitors have been unable to address.

Technical / Clinical Details

The article provides a detailed explanation of the design principles and advancements of PROTACs (Proteolysis-targeting chimeras), which are central to TPD technology. PROTACs are bifunctional molecules that simultaneously bind to a disease-relevant protein and an E3 ubiquitin ligase, thereby inducing the ubiquitination and subsequent proteasomal degradation of the disease-relevant protein. The advantage of TPD lies in its catalytic mechanism of action; a small number of PROTAC molecules can degrade a large number of target proteins, promising potent effects at lower doses than traditional inhibitors. Recent advancements highlighted include: 1) **Utilization of diverse E3 ligases**: Development of PROTACs that recruit new E3 ligases (e.g., MDM2, DCAF15) in addition to conventional VHL and Cereblon has expanded applications to a broader range of target proteins. 2) **Design of orally bioavailable PROTACs**: Molecular design optimization to improve oral bioavailability has enhanced convenience of administration. 3) **Improved pharmacokinetics and pharmacodynamics**: Adjusting linker properties and payload structures has significantly improved PROTACs’ cell permeability, stability, and half-life. These technological innovations have led to an approximate doubling of TPD candidates in clinical development over the past five years.

Background & Context

For decades, drug discovery research primarily focused on small molecules and antibodies that inhibit the activity of enzymes and receptors. However, ‘undruggable’ proteins, especially scaffold proteins and transcription factors lacking enzymatic active sites, which constitute a significant portion of the human genome, were difficult to target with traditional drugs. TPD, by ‘degrading’ these proteins to completely remove their function, is seen as a revolutionary paradigm shift that significantly broadens the scope of drug discovery. Major pharmaceutical companies and emerging biotech firms are making substantial investments in the TPD field, and numerous partnerships have been formed.

Strategic Significance & Outlook

The exponential progression in TPD drug discovery holds the potential to bring revolutionary treatment options across a wide range of disease areas, including oncology, neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s), inflammatory diseases, and viral infections. In the future, more TPD candidates are expected to advance into clinical trials, and their success will establish the firm position of this modality. Research and development will focus on the discovery of novel E3 ligases, further enhancing target specificity, minimizing off-target effects, and optimizing orally bioavailable TPDs. Furthermore, combination therapies involving TPDs with other treatments (e.g., immunotherapies) will be explored to maximize therapeutic effects. TPD is poised to drive innovation in the pharmaceutical industry and bring new hope to patients.

Source: https://www.marinbio.com/exponential-progression-of-targeted-protein-degradation-drug-discovery/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.